Immunology Drugs Market Report Suite for the United States - 2018-2024 - iData Pharma MedSuite
The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases. The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- COMPETITIVE LANDSCAPE
- MARKET TRENDS
- KEY MARKET DEVELOPMENTS
- MARKETS INCLUDED
- VERSION HISTORY
- IDATA PHARMA’S 9-STEP METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecasts and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
- MECHANISM OF ACTION
- 2.1 INTRODUCTION
- 2.1.1 Tumor Necrosis Factor (TNF)
- 2.1.2 B-cell Inhibitors
- 2.1.3 Interleukin Inhibitors
- 2.1.4 Janus Kinase Inhibitors
- 2.1.5 Co-stimulation Modulators
- PRODUCT ASSESSMENT
- 3.1 KEY MARKETED PRODUCTS
- 3.1.1 Abatacept (ORENCIA®)
- 3.1.1.1 Future Developments
- 3.1.1.2 Currently Marketed Products by Company
- 3.1.2 Adalimumab (HUMIRA®)
- 3.1.2.1 Future Developments
- 3.1.2.2 Currently Marketed Products by Company
- 3.1.3 Certolizumab pegol (CIMZIA®)
- 3.1.3.1 Future Developments
- 3.1.3.2 Currently Marketed Products by Company
- 3.1.4 Etanercept (ENBREL®, Benepali®)
- 3.1.4.1 Future Developments
- 3.1.4.2 Currently Marketed Products by company
- 3.1.5 Golimumab (SIMPONI®)
- 3.1.5.1 Future Developments
- 3.1.5.2 Currently Marketed Products by company
- 3.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®)
- 3.1.6.1 Future Developments
- 3.1.6.2 Currently Marketed Products by company
- 3.1.7 Natalizumab (TYSABRI®)
- 3.1.7.1 Currently Marketed Products by company
- 3.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™)
- 3.1.8.1 Future Developments
- 3.1.8.2 Currently Marketed Products by company
- 3.1.9 Tocilizumab (Actemra®/RoActemra®)
- 3.1.9.1 Currently Marketed Products by company
- 3.1.10 Tofacitinib (XELJANZ®)
- 3.1.10.1 Future Developments
- 3.1.10.2 Currently Marketed Products by company
- 3.1.11 Ustekinumab (STELARA®)
- 3.1.11.1 Future Developments
- 3.1.11.2 Currently Marketed Products by company
- 3.1.12 Vedolizumab (ENTYVIO®)
- 3.1.12.1 Currently Marketed Products by company
- 3.2 KEY PRODUCTS IN PIPELINE
- 3.2.1 Barcitinb (Olumiant®)
- 3.2.2 Guselkumab (Tremfya™)
- 3.2.3 Cobitolimod (Kappaproct®)
- 3.2.4 Mavrilimumab
- 3.2.5 Sirukumab
- 3.2.6 Vobarilizumab
- 3.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES
- 3.4 CLINICAL TRIAL BY DISEASE
- 3.4.1 Rheumatoid Arthritis
- 3.4.1.1 Study Completion Date: 2017
- 3.4.1.2 Study Completion Date: 2016 803.4.2 Crohn’s Disease (CD)
- 3.4.2.1 Study Completion Date: 2017
- 3.4.2.2 Study Completion Date: 2016
- 3.4.2.3 Study Completion Date: 2015
- 3.4.3 Ankylosing Spondylitis (AS)
- 3.4.3.1 Study Completion Date: 2017
- 3.4.3.2 Study Completion Date: 2016
- 3.4.3.3 Study Completion Date: 2015
- 3.4.4 Psoriasis (Ps)
- 3.4.4.1 Study Completion Date: 2017
- 3.4.4.2 Study Completion Date: 2016
- 3.4.5 Ulcerative Colitis (UC)
- 3.4.5.1 Study Completion Date: 2016
- 3.4.5.2 Study Completion Date: 2015
- UNITED STATES IMMUNOLOGY MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET OVERVIEW
- 4.3 MARKET SHARE ANALYSIS
- 4.4 DRIVERS AND LIMITERS
- 4.4.1 Market Drivers
- 4.4.2 Market Limiters
- 4.5 COMPETITIVE ANALYSIS
- COUNTRY PROFILE
- 5.1 UNITED STATES
- 5.1.1 Population and Demographics
- 5.1.2 Prevalence of Immunology Diseases
- 5.1.3 Drug Cost Analysis
- 5.1.4 Annual Drug Cost Analysis
- 5.1.5 Disease Treatment Population Size
- 5.1.6 Units of Drugs Sold
- RHEUMATOID ARTHRITIS MARKET
- 6.1 INTRODUCTION
- 6.1.1 Causes and Disease Progression
- 6.1.2 Diagnosis and Treatment Options
- 6.1.3 Symptoms and Complications
- 6.1.4 Epidemiology
- 6.2 MARKET OVERVIEW
- 6.3 MARKET SHARE ANALYSIS
- CROHN’S DISEASE MARKET
- 7.1 INTRODUCTION
- 7.1.1 Causes and Disease Progression
- 7.1.2 Diagnosis and Treatment Options
- 7.1.3 Symptoms and Complications
- 7.1.4 Epidemiology
- 7.2 MARKET OVERVIEW
- 7.3 TREND ANALYSIS
- ANKYLOSING SPONDYLITIS MARKET
- 8.1 INTRODUCTION
- 8.1.1 Causes and Disease Progression
- 8.1.2 Diagnosis and Treatment Options
- 8.1.3 Symptoms and Complications
- 8.1.4 Epidemiology
- 8.2 MARKET OVERVIEW
- 8.3 TREND ANALYSIS
- PSORIASIS MARKET
- 9.1 INTRODUCTION
- 9.1.1 Causes and Disease Progression
- 9.1.2 Diagnosis and Treatment Options
- 9.1.3 Symptoms and Complications
- 9.1.4 Epidemiology
- 9.2 MARKET OVERVIEW
- 9.3 TREND ANALYSIS
- ULCERATIVE COLITIS MARKET
- 10.1 INTRODUCTION
- 10.1.1 Causes and Disease Progression
- 10.1.2 Diagnosis and Treatment Options
- 10.1.3 Symptoms and Complications
- 10.1.4 Epidemiology
- 10.2 MARKET OVERVIEW
- 10.3 TREND ANALYSIS 207COMPANY PROFILES
- 11.1 ABBVIE INC.
- 11.1.1 Business Overview
- 11.1.2 Financials
- 11.1.3 SWOT Analysis
- 11.1.3.1 Strengths:
- 11.1.3.2 Weakness:
- 11.1.3.3 Opportunity:
- 11.1.3.4 Threats:
- 11.2 AMGEN INC.
- 11.2.1 Business Overview
- 11.2.2 Financials
- 11.2.3 SWOT Analysis
- 11.2.3.1 Strengths:
- 11.2.3.2 Weaknesses:
- 11.2.3.3 Opportunities:
- 11.2.3.4 Threats:
- 11.3 BIOGEN IDEC
- 11.3.1 Business Overview
- 11.3.2 Financials
- 11.3.3 SWOT Analysis
- 11.3.3.1 Strengths:
- 11.3.3.2 Weakness:
- 11.3.3.3 Opportunities:
- 11.3.3.4 Threats:
- 11.4 BRISTOL-MYERS SQUIBB
- 11.4.1 Business Overview
- 11.4.2 Financials
- 11.4.3 SWOT Analysis
- 11.4.3.1 Strengths:
- 11.4.3.2 Weakness:
- 11.4.3.3 Opportunities:
- 11.4.3.4 Threats:
- 11.5 HOFFMANN-LA ROCHE LTD
- 11.5.1 Business Overview
- 11.5.2 Financials
- 11.5.3 SWOT Analysis
- 11.5.3.1 Strengths:
- 11.5.3.2 Weakness:
- 11.5.3.3 Opportunities:
- 11.5.3.4 Threats:
- 11.6 JOHNSON & JOHNSON/JANSSEN
- 11.6.1 Business Overview
- 11.6.2 Financials
- 11.6.3 SWOT Analysis
- 11.6.3.1 STRENGTHS:
- 11.6.3.2 Weakness:
- 11.6.3.3 Opportunities:
- 11.6.3.4 Threats:
- 11.7 NOVARTIS AG
- 11.7.1 Business Overview
- 11.7.2 Financials
- 11.7.3 SWOT Analysis
- 11.7.3.1 STRENGTHS:
- 11.7.3.2 Weakness:
- 11.7.3.3 Opportunities:
- 11.7.3.4 Threats:
- 11.8 PFIZER INC.
- 11.8.1 Business Overview
- 11.8.2 Financials
- 11.8.3 SWOT Analysis
- 11.8.3.1 Strengths:
- 11.8.3.2 Weakness
- 11.8.3.3 Opportunities
- 11.8.3.4 Threats:
- 11.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 11.9.1 Business Overview
- 11.9.2 Financials
- 11.9.3 SWOT Analysis
- 11.9.3.1 Strengths:
- 11.9.3.2 Weakness:
- 11.9.3.3 Opportunities
- 11.9.3.4 Threats:
- 11.10 UCB S.A.
- 11.10.1 Business Overview
- 11.10.2 Financials
- 11.10.3 SWOT Analysis
- 11.10.3.1 Strengths:
- 11.10.3.2 Weakness:
- 11.10.3.3 Opportunities:
- 11.10.3.4 Threats:
- ABBREVIATIONS
- APPENDIX: COMPANY PRESS RELEASES
- List of Charts
- Chart 1 1: Immunology Market by Segment, U.S., 2013 – 2023
- Chart 1 2: Immunology Market Overview, U.S., 2016 & 2023
- Chart 4 1: Immunology Market by Segment, U.S., 2014 – 2024
- Chart 4 2: Immunology Market Breakdown, U.S., 2017
- Chart 4 3: Immunology Market Breakdown, U.S., 2024
- Chart 4 7: Market Share Analysis, Immunology Market, U.S., 2014 – 2024
- Chart 4 8: Leading Competitors, Immunology Market, U.S., 2017
- Chart 6 1: Rheumatoid Arthritis Market by Segment, U.S., 2014 – 2024
- Chart 6 2: Rheumatoid Arthritis Market Breakdown, U.S., 2017
- Chart 6 3: Rheumatoid Arthritis Market Breakdown, U.S., 2024
- Chart 6 4: Growth Rates by Segment, Rheumatoid Arthritis Market, U.S., 2014 – 2024
- Chart 6 5: Leading Competitors, Rheumatoid Arthritis Market, U.S., 2017
- Chart 7 1: Crohn’s Disease Market by Segment, U.S., 2014 – 2024
- Chart 7 2: Crohn’s Disease Market Breakdown, U.S., 2017
- Chart 7 3: Crohn’s Disease Market Breakdown, U.S., 2024
- Chart 7 4: Growth Rates by Segment, Crohn’s Disease Market, U.S., 2014 – 2024
- Chart 7 5: Leading Competitors, Crohn’s Disease Market, U.S., 2017
- Chart 8 1: Ankylosing Spondylitis Market by Segment, U.S., 2014 – 2024
- Chart 8 2: Ankylosing Spondylitis Market Breakdown, U.S., 2017
- Chart 8 3: Ankylosing Spondylitis Market Breakdown, U.S., 2024
- Chart 8 4: Growth Rates by Segment, Ankylosing Spondylitis Market, U.S., 2014 – 2024
- Chart 8 5: Leading Competitors, Ankylosing Spondylitis Market, U.S., 2017
- Chart 9 1: Psoriasis Market by Segment, U.S., 2014 – 2024
- Chart 9 2: Psoriasis Market Breakdown, U.S., 2017
- Chart 9 3: Psoriasis Market Breakdown, U.S., 2024
- Chart 9 4: Growth Rates by Segment, Psoriasis Market, U.S., 2014 – 2024
- Chart 9 5: Leading Competitors, Psoriasis Market, U.S., 2017
- Chart 10 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024
- Chart 10 2: Ulcerative Colitis Market Breakdown, U.S., 2017
- Chart 10 3: Ulcerative Colitis Market Breakdown, U.S., 2024
- Chart 10 4: Growth Rates by Segment, Ulcerative Colitis Market, U.S., 2014 – 2024
- Chart 10 5: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
- Chart 11 1: Enbrel® Revenue, 2012-2016
- List of Figures
- Figure 1 1: Immunology Market Share Ranking by Segment, U.S., 2017
- Figure 1 2: Companies Researched in this Report, U.S., 2017
- Figure 1 3: Factors Impacting the Immunology Market
- Figure 1 4: Recent Events in the Immunology Market, Global, 2016 – 2017, AbbVie
- Figure 1 5: Recent Events in the Immunology Market, Global, 2016 – 2017, Amgen
- Figure 1 6: Recent Events in the Immunology Market, Global, 2016 – 2017, AstraZeneca
- Figure 1 7: Recent Events in the Immunology Market, Global, 2016 – 2017, Biogen
- Figure 1 8: Recent Events in the Immunology Market, Global, 2016 – 2017, BMS
- Figure 1 9: Recent Events in the Immunology Market, Global, 2016 – 2017, Eli Lilly
- Figure 1 10: Recent Events in the Immunology Market, Global, 2016 – 2017, Roche
- Figure 1 11: Recent Events in the Immunology Market, Global, 2016 – 2017, Janssen
- Figure 1 12: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
- Figure 1 13: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
- Figure 1 14: Recent Events in the Immunology Market, Global, 2016 – 2017, Pfizer
- Figure 1 15: Recent Events in the Immunology Market, Global, 2016 – 2017, Takeda
- Figure 1 16: Recent Events in the Immunology Market, Global, 2016 – 2017, UCB
- Figure 1 17: Immunology Markets Covered, U.S., 2016 (1 of 2)
- Figure 1 18: Immunology Markets Covered, U.S., 2016 (2 of 2)
- Figure 1 19: Version History
- Figure 2 1: Classification by Mechanism of Action
- Figure 3 1: Marketed Product Portfolio by Company
- Figure 3 2: Marketed Product Portfolio by Company
- Figure 3 3: Marketed Product Portfolio by Company
- Figure 3 4: Marketed Product Portfolio by Company
- Figure 3 5: Marketed Product Portfolio by Company
- Figure 3 6: Marketed Product Portfolio by Company
- Figure 3 7: Marketed Product Portfolio by Company
- Figure 3 8: Marketed Product Portfolio by Company
- Figure 3 9: Marketed Product Portfolio by Company
- Figure 3 10: Marketed Product Portfolio by Company
- Figure 3 11: Marketed Product Portfolio by Company
- Figure 3 12: Marketed Product Portfolio by Company
- Figure 3 13: Other products in pipeline
- Figure 3 14: Pipeline Product Portfolio by Company (1 of 5)
- Figure 3 15: Pipeline Product Portfolio by Company (2 of 5)
- Figure 3 16: Pipeline Product Portfolio by Company (3 of 5)
- Figure 3 17: Pipeline Product Portfolio by Company (4 of 5)
- Figure 3 18: Pipeline Product Portfolio by Company (5 of 5)
- Figure 3 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA)
- Figure 3 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS)
- Figure 3 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE)
- Figure 3 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
- Figure 3 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA
- Figure 3 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
- Figure 3 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis
- Figure 3 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)
- Figure 3 27: Abatacept Post-marketing Clinical Study in Japan
- Figure 3 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY)
- Figure 3 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
- Figure 3 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE)
- Figure 3 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Figure 3 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
- Figure 3 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
- Figure 3 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
- Figure 3 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
- Figure 3 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis
- Figure 3 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)
- Figure 3 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
- Figure 3 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
- Figure 3 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
- Figure 3 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)
- Figure 3 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
- Figure 3 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
- Figure 3 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC)
- Figure 3 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT)
- Figure 3 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
- Figure 3 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C)
- Figure 3 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR)
- Figure 3 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)
- Figure 3 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- Figure 3 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
- Figure 3 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
- Figure 3 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)
- Figure 3 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
- Figure 3 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
- Figure 3 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
- Figure 3 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
- Figure 3 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
- Figure 3 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA) 96Figure 3 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
- Figure 3 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
- Figure 3 62: Adalimumab-psoriasis and Small Bowel Lesions
- Figure 3 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
- Figure 3 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
- Figure 3 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX)
- Figure 3 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
- Figure 3 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA)
- Figure 3 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
- Figure 3 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis
- Figure 3 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
- Figure 3 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS)
- Figure 3 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY)
- Figure 3 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD)
- Figure 3 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
- Figure 3 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis
- Figure 3 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis
- Figure 3 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA®
- Figure 3 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR)
- Figure 3 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)
- Figure 3 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)
- Figure 3 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)
- Figure 3 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
- Figure 3 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)
- Figure 3 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)
- Figure 3 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN) 109Figure 3 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E)
- Figure 3 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
- Figure 3 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS)
- Figure 3 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE)
- Figure 3 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
- Figure 3 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)
- Figure 3 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
- Figure 3 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
- Figure 3 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
- Figure 3 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis 114Figure 3 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)
- Figure 3 97: Adalimumab-psoriasis and Small Bowel Lesions
- Figure 3 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND) 116Figure 3 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
- Figure 3 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS)
- Figure 3 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
- Figure 3 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
- Figure 3 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3)
- Figure 3 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)
- Figure 3 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)
- Figure 3 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
- Figure 3 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis
- Figure 3 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP)
- Figure 3 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART)
- Figure 3 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients 122Figure 3 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)
- Figure 3 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)
- Figure 3 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda)
- Figure 3 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
- Figure 4 1: Immunology Market by Segment, U.S., 2014 – 2024 (US$M) (1 of 2)
- Figure 4 2: Immunology Market by Segment, U.S., 2014 – 2024 (US$M) (2 of 2)
- Figure 4 4: Immunology Market Share Analysis by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 4 5: Immunology Market Share Analysis by Segment, U.S., 2014 – 2024 (2 of 2)
- Figure 4 6: Rheumatoid Arthritis Prevalence Statistics, by Age and Gender, U.S., 2014
- Figure 4 7: Patent Expiries of Marketed Drugs in Immunology
- Figure 4 8: Drivers and Limiters, Immunology Market, U.S., 2017
- Figure 4 9: Leading Competitors, Immunology Market, U.S., 2017
- Figure 5 1: Prevalence of the immunology diseases in the U.S., 2017
- Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017
- Figure 5 3: Treatment Population Size of Crohn’s Disease, U.S., 2017
- Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017
- Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017
- Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017
- Figure 5 7: List of U.S. Retail Pharmacies
- Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2)
- Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2)
- Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S.
- Figure 6 1: Rheumatoid Arthritis Market by Segment, U.S., 2014 – 2024 (US$M) (1 of 2)
- Figure 6 2: Rheumatoid Arthritis Market by Segment, U.S., 2014 – 2024 (US$M) (2 of 2)
- Figure 6 3: Rheumatoid Arthritis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 6 4: Rheumatoid Arthritis Market Growth by Segment, U.S., 2014 – 2024 (2 of 2)
- Figure 6 5: Leading Competitors, Rheumatoid Arthritis Market, U.S., 2017
- Figure 7 1: Crohn’s Disease Market by Segment, U.S., 2014 – 2024 (US$M) (1 of 2)
- Figure 7 2: Crohn’s Disease Market by Segment, U.S., 2014 – 2024 (US$M) (2 of 2)
- Figure 7 3: Crohn’s Disease Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 7 4: Crohn’s Disease Market Growth by Segment, U.S., 2014 – 2024 (2 of 2)
- Figure 7 5: Leading Competitors, Crohn’s Disease Market, U.S., 2017
- Figure 8 1: Ankylosing Spondylitis Market by Segment, U.S., 2014 – 2024 (US$M)
- Figure 8 2: Ankylosing Spondylitis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 8 3: Leading Competitors, Ankylosing Spondylitis Market, U.S., 2017
- Figure 9 1: Psoriasis Market by Segment, U.S., 2014 – 2024 (US$M)
- Figure 9 2: Psoriasis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 9 3: Leading Competitors, Psoriasis Market, U.S., 2017
- Figure 10 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024 (US$M)
- Figure 10 2: Ulcerative Colitis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 10 3: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
- Figure 11 1: Key Facts, AbbVie Inc., 2017
- Figure 11 2: Financials, AbbVie Inc., 2017
- Figure 11 3: SWOT Analysis, AbbVie Inc., 2017
- Figure 11 4: Key Facts, Amgen, 2017
- Figure 11 5: Financial Overview, Amgen, 2017
- Figure 11 6: SWOT Analysis, Amgen, 2017
- Figure 11 7: Patent Expiries, Enbrel®
- Figure 11 8: Key Facts, Biogen Idec
- Figure 11 9: Financials, Biogen Idec, 2017
- Figure 11 10: SWOT Analysis, Biogen Idec
- Figure 11 11: Key Facts, Bristol-Myers Squibb
- Figure 11 12: Financials, Bristol-Myers Squibb, 2017
- Figure 11 13: Bristol-Myers Squibb, Key Products Revenue (US$M)
- Figure 11 14: SWOT Analysis, Bristol-Myers Squibb
- Figure 11 15: Key Facts, Hoffman-La Roche Ltd
- Figure 11 16: Financials, Hoffman-La Roche Ltd , 2017
- Figure 11 17: SWOT Analysis, Hoffman-La Roche Ltd 239Figure 11 18: Key Facts, Johnson & Johnson
- Figure 11 19: Financials, Johnson & Johnson, 2017
- Figure 11 20: SWOT Analysis, Johnson & Johnson
- Figure 11 21: Key Facts, Novartis AG
- Figure 11 22: Financials, Novartis AG, 2017
- Figure 11 23: SWOT Analysis, Novartis AG
- Figure 11 24: Key Facts, Pfizer Inc.
- Figure 11 25: Financials, Pfizer Inc., 2017
- Figure 11 26: SWOT Analysis, Pfizer Inc.
- Figure 11 27: Key Facts, Takeda Pharmaceutical Company Limited
- Figure 11 28: Financials, Takeda Pharmaceutical Company Limited , 2017
- Figure 11 29: SWOT Analysis, Takeda Pharmaceutical Company Limited
- Figure 11 30: Key Facts, UCB S.A.
- Figure 11 31: Financials, UCB S.A., 2017
- Figure 11 32: SWOT Analysis, UCB S.A.
- Figure 13 1: Press Release Summary